

EDITORIAL ADVISORY PANEL

- N. H. Andersen (Aarhus)
C. Austin (Manchester)
D. Bhatnagar (Oldham)
I. Biaggioni (Nashville, TN)
C. E. Brightling (Leicester)
A. Burt (Newcastle upon Tyne)
D. Callen (Adelaide, S. Aus.)
J. D. Cameron (Dandenong, Vic.)
V. Cameron (Christchurch, NZ)
A. Carter (Leeds)
J. P. F. Chin-Dusting (Melbourne)
P. Chowienczyk (London)
J. de Graaf (Nijmegen)
S. Duthie (Aberdeen)
K. Evans (Stafford)
A. Ferrante (North Adelaide)
J. Floras (Toronto)
G. A. Ford (Newcastle upon Tyne)
D. Freeman (Glasgow)
L.-M. Gan (Goteburg)
B. Garner (Sydney)
G. J. Gibson (Newcastle upon Tyne)
S. Gough (Birmingham)
A. Graham (Glasgow)
G. Grassi (Milan)
D. J. Green (Nedlands, WA)
M. Grimm (Kogarah, NSW)
N. Haites (Aberdeen)
J. D. Imig (Augusta, GA)
E. W. Inscho (Augusta, GA)
B. Jilma (Vienna)
J. T. Kielstein (Stanford, CA)
D. S. Kumaratne (Cambridge)
T. Kuo (Hualien)
P. Little (Melbourne)
D. Lobo (Nottingham)
R. A. Malik (Manchester)
P. G. McTernan (Coventry)
J. Mullins (Edinburgh)
S. Nagueh (Houston, TX)
- L. Ng (Leicester)
T. Nyström (Stockholm)
M. J. O'Leary (Sydney)
T. Omland (Oslo)
G. Parati (Milan)
P. Pérez-Martínez (Cordoba)
S. Phillips (Hamilton)
M. Rademaker (Christchurch, NZ)
J. Rhodes (Liverpool)
R. Rush (Adelaide)
C. Schalkwijk (Maastricht)
M. Schillinger (Vienna)
F. C. Schmalstieg, Jr (Galveston)
T. Shimosawa (Tokyo)
C. C. Shoulders (London)
S. S. Smyth (Lexington, KY)
I. Squire (Leicester)
J. Staessen (Leuven)
H. Stauss (Berlin)
I. Striz (Prague)
D.-F. Su (Shanghai)
S. R. Thomas (Sydney)
N. C. Thomson (Glasgow)
V. Thongboonkerd (Bangkok)
H. Tomiyama (Tokyo)
M. van der Giet (Berlin)
J. J. Van Lieshout (Amsterdam)
M. Verma (Bethesda)
S. Watts (East Lansing)
M. Weiss (Munich)
J. Wernerman (Huddinge)
M. J. White (Birmingham)
J. Wilson (Bankstown, NSW)
R. Woodman (Perth, WA)
S. Ye (London)
C.-M. Yu (Hong Kong)
C. Zeng (Chongqing City)
C. Zhang (Newark)
J. Zicha (Prague)

Clinical SCIENCE

AN INTERNATIONAL JOURNAL OF CLINICAL & MOLECULAR INVESTIGATION

VOLUME 114 : 2008

EDITORIAL BOARD

Editor-in-Chief

R. Clinton Webb

Reviews Editor

Rhian Touyz

Associate Editors

David Adams

Nigel Brunskill

Philip Calder

Stephen Holgate

Jonathan Lamb

Chim Lang

Mhairi Macrae

Nilesh Samani

Gerald Watts

Editors

Louise Burrell

Peter Clifton

Kevin Croft

Alan Daugherty

Christian Delles

Jean-Francois Dufour

Peter Emery

Claudio Ferri

Ian Godsland

Aroon Hingorani

Cathy Holt

Richard James

Anna Kurdowska

Maria Teresa La Rovere

Janice Marshall

Kevin McCully

Gary McVeigh

James Meschia

Patricia Munroe

Philip Newsholme

Kevin O'Shaughnessy

Aled Phillips

Michael Polkey

Josep Redon

Naveed Sattar

Åke Sjöholm

Allan Sniderman

Mark Swain

Ingo Tamm

Brenda Williams

Ian Young

Neurobiology
Transport
Metabolism
Molecular Cell Biology
Respiratory
Nutrition
Gastroenterology
Vascular Physiology
Kinetics
Diabetes
Cardiovascular
Hypertension
Molecular Biology
Stem Cell Biology
Cell Biology
Molecular Biology
Vascular Physiology
Kinetics
Diabetes
Cardiovascular
Hypertension
Molecular Biology
Stem Cell Biology
Cell Biology
Molecular Biology

**Published by Portland Press on behalf of the
Biochemical Society**

© **The Biochemical Society 2008**

ISSN 0143-5221

Printed in Great Britain by the Charlesworth Group, Wakefield

A U T H O R I N D E X

- A**bdul-Hussien, H. 687–697
 Abel, E.D. 195–210
 Aguila, M. B. 381–392
 Aguilar, S. 99–108
 Aguilera, C. M. 183–193
 Aimalohi, E. 321–329
 Allen, T. C. 403–412
 Alp, N. J. 509–531
 Altavilla, D. 707–718
 Amirahmadi, F. 157–164
 Araya, J. 625–634
 Armah, C. K. 679–686
 Arribas, S. M. 651–659
 Asano, M. 431–440
 Assaly, R. A. 123–130
 Azizi, M. 123–130
- B**ächler, J. P. 625–634
 Barreto-Chaves, M. L. M. 375–380
 Barrett, P. H. R. 611–624
 Barry, M. K. 339–346
 Basili, S. 449–455
 Bast, A. 553–560
 Battaglia, M. 413–421
 Belch, J. J. F. 561–566
 Bellastella, A. 413–421
 Bellastella, G. 413–421
 Beloqui, Ó. 173–182
 Berbée, M. 231–241
 Berg, G. A. 423–430
 Bergeron, J. 149–155
 Bergsten, P. 499–507
 Berne, C. 499–507
 Berry, C. 423–430
 Bilfinger, T. V. 339–346
 Bitto, A. 707–718
 Bizzarro, A. 413–421
 Born, W. 49–58
 Bouter, L. M. 479–487
 Bradley, T. D. 243–249
 Bramanti, F. 489–497
 Bremer, H. -C. 165–171
 Brillante, D. G. 139–147
 Brouwers, M. C. G. J. 393–401
- Brown, J. 441–447
 Bugger, H. 195–210
 Burrell, L. M. 313–320
 Burton-Freeman, B. 331–337
 Buurman, W. A. 231–241
- C**alafiore, P. 313–320
 Callera, G. E. 85–97
 Calò, M. 707–718
 Cañete, R. 183–193
 Carlier, S. G. 441–447
 Carneiro-Ramos, M. S. 375–380
 Carvalho, M. H. C. 85–97
 Casarini, D. E. 375–380
 Caso, G. 339–346
 Chan, D. C. 611–624
 Charles, C. J. 635–642
 Cheghani, F. 679–686
 Cheng, K. K. Y. 361–374
 Conde, M. V. 651–659
 Conte, M. 413–421
 Corne, J. 533–541
 Coronella, C. 413–421
 Couture, P. 149–155
 Cox, R. A. 321–329
 Crocenzi, F. A. 567–588
 Cryer, P. E. 589–590
- D**argie, H. J. 423–430
 da Silva Morais, A. 73–83
 Davi, G. 449–455
 De Bellis, A. 413–421
 de Bruin, T. W. A. 393–401
 de Graaf, J. 393–401
 Dejong, C. H. C. 231–241, 553–560
 Dekker, J. M. 479–487
 Delles, C. 423–430
 Deutz, N. E. P. 231–241
 Di Pasquale, P. 221–230
 Díez, J. 173–182
 Dignam, J. D. 123–130
 Doman, I. 679–686
 Dominiczak, A. F. 423–430
- Dorrance, A. M. 37–47
 Downey, M. 441–447
 Du, X. -J. 157–164
 Dufour, J. -F. 467–477
- E**dirisinghe, I. 331–337
 Ehlken, N. 165–171
 El Haber, N. 719–727
 Emdin, M. 489–497
 Enkhbaatar, P. 321–329
 Erbas, B. 719–727
- F**airclough, L. 533–541
 Falco, A. 449–455
 Fasullo, S. 221–230
 Faure, P. 251–256
 Favier, A. 251–256
 Fernández-Alfonso, M. S. 651–659
 Ferrero, V. 211–220
 Ferroni, P. 449–455
 Fischer, J. A. 49–58
 Fischer, M. A. J. G. 553–560
 Fiumara, T. 707–718
 Floras, J. S. 243–249
 Fortes, Z. B. 85–97
 Fortuño, A. 173–182
 Foster, J. E. 423–430
 Franco, M. C. P. 375–380
 Fu, C. 131–137
 Fudala, R. 403–412
 Fujino, N. 431–440, 643–650
- G**agné, C. 149–155
 Galeano, M. R. 707–718
 Gan, S. K. 543–545
 Garlick, P. J. 339–346
 Gaspare, P. 221–230
 Georgieva, A. M. 393–401
 Ghofrani, H. A. 165–171
 Giacca, M. 707–718
 Giannoni, A. 489–497
 Gidlöf, A. C. 19–25
 Gil, Á. 183–193
 Gil-Campos, M. 183–193
- Gilman, M. P. 243–249
 González, J. M. 651–659
 González, M. C. 651–659
 Götz, J. 49–58
 Graham, R. M. 157–164
 Grimm, C. 49–58
 Grimm, D. 305–311
 Gruenig, E. 165–171
 Guadagni, F. 449–455
 Guagnano, M. T. 449–455
- H**abib, R. H. 123–130
 Hafezi, F. 49–58
 Hägerkvist, R. 65–71
 Halank, M. 165–171
 Halimi, S. 251–256
 Haluska, B. A. 441–447
 Hamahata, A. 321–329
 Hampton, M. B. 293–304
 Han, Y. 131–137
 Hänsch, J. 305–311
 Hanssen, S. J. P. 231–241
 Hawn, T. R. 347–360
 Hayashi, K. 643–650
 Heine, R. J. 479–487
 Herndon, D. N. 321–329
 Higashikata, T. 643–650
 Hill, A. 561–566
 Hill, K. D. 719–727
 Hoeper, M. M. 165–171
 Hogue, J. -C. 149–155
 Horsmans, Y. 73–83
 Howes, L. G. 139–147
 Hui, R. 131–137
 Husmann, K. 49–58
 Hyltander, A. 603–610
- I**no, H. 431–440, 643–650
 Iresjö, B. -M. 603–610
 Ishibashi-Ueda, H. 643–650
 Ittner, L. M. 49–58
- J**ackson, K. G. 679–686
 Jakobs, C. 479–487
 James, L. 679–686
 Janes, S. M. 99–108

- Jansson, L. 65–71
Januzzi, J. L. 289–291
Jeffriess, L. 441–447
Jensen, F. T. 547–552
Jerums, G. 313–320
Johnstone, M. T. 139–147
Jorgensen, J. O. L. 547–552
- K**
Kabitz, H. -J. 165–171
Kaneda, T. 431–440
Kaneko, Y. 243–249
Kappagoda, C. T. 331–337
Kavouras, S. A. 59–64
Kawashima, A. 431–440
Kawashiri, M. -a. 643–650
Keenan, J. I. 293–304
Kennedy, G. 561–566
Kennedy, S. 265–273
Kerckelä, R. 293–304
Khan, F. 561–566
Kleemann, R. 687–697
Klose, H. 165–171
Koek, G. H. 553–560
Konno, T. 431–440,
643–650
Körner, U. 603–610
Kossmehl, P. 305–311
Kreutz, R. 305–311
Krivospitskaya, O. 19–25
Krupa, A. 403–412
Kunz, T. H. 49–58
Kurdowska, A. K. 403–412
Kurrer, M. O. 49–58
- L**
Lam, K. S. L. 361–374
Lamb, J. R. 533–541
Lang, K. S. 49–58
Lange, M. 321–329
Leclercq, I. 73–83
Leung, R. S. T. 243–249
Levine, D. Z. 109–118
Li, X. C. 591–601
Liao, T. -d. 591–601
Lindeman, J. H. N. 687–697
Ljungman, D. 603–610
Lo Cascio, P. 707–718
Loebinger, M. R. 99–108
Lundholm, K. 603–610
- Ma**
Maclsaac, R. J. 313–320
Magkos, F. 59–64
Mandarim-de-Lacerda, C.
A. 381–392
Manigrasso, M. R. 449–455
Marwick, T. H. 441–447
McNurlan, M. A. 339–346
- Michetti, N. 449–455
Minihane, A. M. 679–686
Minutoli, L. 707–718
Misch, E. A. 347–360
Mittendorfer, B. 59–64
Miyamoto, S. 643–650
Moller, L. 547–552
Monbaliu, D. 231–241
Montezano, A. C. 85–97
Mori, S. 431–440
Moschen, A. R. 275–288
Muff, R. 49–58
- N**
Nakano, Y. 321–329
Namura, M. 431–440
Naruse, C. 431–440
Nicholls, M. G. 635–642
Nijpels, G. 479–487
Nunoda, S. 431–440
Nuyt, A. M. 1–17
- O**
Ocaya, P. 19–25
Oldroyd, K. G. 265–273
Ooi, E. M. M. 611–624
O'Shaughnessy, K. M.
661–677
Oshima, T. 431–440
Osmond, J. M. 37–47
O'Sullivan, A. J. 139–147
- P**
Pane, E. 413–421
Paoletti, V. 449–455
Passalacqua, W. 625–634
Passino, C. 489–497
Patel, S. K. 313–320
Paterna, S. 221–230
Pemberton, C. J. 293–304
Piepoli, M. 489–497
Piguet, A. -C. 467–477
Pinheiro, A. R. 381–392
Pihola, J. 293–304
Polak, B. C. P. 479–487
Poletti, R. 489–497
Polge, C. 251–256
Polito, F. 707–718
Prat, H. 625–634
Prontera, C. 489–497
Prough, D. S. 321–329
Pugno, F. 211–220
- R**
Rademaker, M. T. 635–642
Ribichini, F. 211–220
Richards, A. M. 293–304,
635–642
Rigsby, C. S. 37–47
Rodrigo, R. 625–634
- Roelen, D. L. 687–697
Roma, M. G. 567–588
Romanque, P. 467–477
Ruocco, G. 413–421
- S**
Sakamoto, A. 643–650
Saliez, A. 73–83
Salvucci, I. D. M. 381–392
Sánchez Pozzi, E. A.
567–588
San José, G. 173–182
Santilli, F. 449–455
Sarullo, F. M. 221–230
Sawaya, A. L. 375–380
Schaapherder, A. F. M.
687–697
Schaefer, V. 165–171
Schlesener, M. 305–311
Schulz, A. 305–311
Schwerdtfeger, K. 49–58
Schwoerer, A. 165–171
Sess, R. 375–380
Shapiro, J. I. 123–130
Sidossis, L. S. 59–64
Sinisi, A. A. 413–421
Sirsjö, A. 19–25
Sniderman, A. D. 149–155
Somoza, B. 651–659
Song, X. 131–137
Sonntag, F. 165–171
Spence, V. A. 561–566
Squadrito, F. 707–718
Srivastava, P. M. 313–320
Stahler, G. 165–171
Stalenhoef, A. F. 393–401
Stankowska, D. A. 403–412
Stärkel, P. 73–83
Steedman, T. 423–430
Stehouwer, C. D. A.
393–401, 479–487
Stodkilde-Jorgensen, H.
547–552
Stolk, R. P. 479–487
Sugamoto, Y. 643–650
Sun, K. 131–137
Sundsten, T. 499–507
Swain, M. G. 457–466
- T**
Takeda, Y. 643–650
Teerlink, T. 479–487
ter Avest, E. 393–401
Thomas, M. C. 313–320
Tilg, H. 275–288
Tirelli, G. 413–421
Tostes, R. C. 85–97
Touyz, R. M. 85–97
- Traber, D. L. 321–329
Traber, L. D. 321–329
Trapani, V. 27–35
Tsekouras, Y. 59–64
Turnbull, L. 157–164
- U**
Urbanowicz, R. A. 533–541
Usui, K. 243–249
- V**
Vacca, G. 211–220
van Bockel, J. H. 687–697
van de Poll, M. C. G.
231–241, 553–560
van der Kallen, C. J. H.
393–401
Van Der Meer, P. 289–291
van Greevenbroek, M. M. J.
393–401
van Hecke, M. V. 479–487
Vanhoutte, P. M. 361–374
van Veldhuisen, D. J.
289–291
Vassanelli, C. 211–220
Vetter, R. 305–311
Virmani, R. 211–220
von der Thüsen, J. H.
687–697
Vosswinkel, J. A. 339–346
- W**
Wadsworth, R. 265–273
Walker, D. 165–171
Walterspacher, S. 165–171
Wang, H. 131–137
Wang, J. 321–329
Wang, S. 131–137
Wark, J. D. 719–727
Watson, C. 509–531
Watt, J. 265–273
Watts, G. F. 543–545,
611–624
Webb, R. C. 85–97
Weiss, J. 305–311
Welsh, N. 65–71
Wendt, N. 305–311
Wiernsperger, N. 251–256
Wijns, W. 211–220
Windisch, W. 165–171
Wolf, F. I. 27–35
Woodcock, E. A. 157–164
Woodman, R. J. 119–121
- X**
Xu, A. 361–374
Xue, H. 131–137
- Y**
Yagi, K. 643–650

Yamagishi, M. 431–440,
643–650
Yasmin 661–677

Zalba, G. 173–182
Zargham, R. 257–264
Zentilin, L. 707–718

Zethelius, B. 499–507
Zhang, C. 699–706
Zhang, W. 131–137

Zhu, W. 361–374
Zhuo, J. L. 591–601
Zimmerli, L. U. 423–430

S U B J E C T I N D E X

- A**bdominal aortic aneurysm
inflammation, transcription factor
687–697
- Acute lung injury
anticoagulant, burn 321–329
autoantibody, interleukin-8
403–412
- Adiponectin
cardiovascular disease, obesity
361–374
obesity, visfatin 275–288
- Adrenergic receptor
Ins(1,4,5)P₃, ischaemia/reperfusion
157–164
- Adrenomedullin
calcitonin receptor-like protein,
glaucoma 49–58
- Age
balance, muscle strength 719–727
- Airway
lung disease, stem cell 99–108
- Albumin
antioxidant, Type 2 diabetes
251–256
- Albuminuria
gender, quantitative trait locus
305–311
- Aldosterone
mineralocorticoid receptor, stroke
37–47
- Angiogenesis
hepatocellular carcinoma,
inflammation 467–477
- Angioplasty
coronary artery bypass grafting,
pathology 211–220
remodelling, restenosis 257–264
- Angiopoietin
diabetes, wound healing 707–718
- Angiotensin II type I receptor
arterial stiffness, insulin resistance
119–121, 139–147
- Angiotensin-converting enzyme
heart failure, urocortin 2 635–642
- Anticoagulant
acute lung injury, burn 321–329
- Antioxidant
albumin, Type 2 diabetes 251–256
drug-eluting stent, oxidative stress
265–273
ischaemia/reperfusion, liver
553–560
- Apolipoprotein B
dyslipidaemia, high-density
lipoprotein 149–155
- Apolipoprotein C-III
cardiovascular disease, metabolic
syndrome 611–624
- Arginase-I
hepatocyte, liver resection 231–241
- Arterial function
distensibility coefficient, tissue
Doppler imaging 441–447
- Arterial stiffness
angiotensin II type I receptor,
insulin resistance 119–121,
139–147
biomarker, cardiovascular disease
661–677
chronic fatigue syndrome,
inflammation 561–566
- Atherosclerosis
cardiovascular disease, *Chlamydia
pneumoniae* 509–531
chemotaxis, ephrin-B 643–650
percutaneous coronary
intervention, vitamin A 19–25
- Atrial natriuretic peptide
gene polymorphism, left ventricular
hypertrophy 131–137
- Autoantibody
acute lung injury, interleukin-8
403–412
- Autoimmune disease
lymphocytic hypophysitis, pituitary
gland 413–421
- B**alance
age, muscle strength 719–727
- Bile
cholestasis, hepatocellular
transport 567–588
- Biomarker
arterial stiffness, cardiovascular
disease 661–677
- Birthweight
catecholamine, renin–angiotensin
system 375–380
- Blood pressure
cardiovascular disease,
developmental programming
1–17
- Burn
acute lung injury, anticoagulant
321–329
- C**alcitonin receptor-like protein
adrenomedullin, glaucoma
49–58
- Cardiac magnetic resonance
coronary artery bypass grafting,
risk stratification 423–430
- Cardiomyopathy
left ventricular hypertrophy, myosin
heavy chain 431–440
- Cardiovascular disease
adiponectin, obesity 361–374
apolipoprotein C-III, metabolic
syndrome 611–624
arterial stiffness, biomarker
661–677
atherosclerosis, *Chlamydia
pneumoniae* 509–531
blood pressure, developmental
programming 1–17
metabolic syndrome,
mitochondrion 195–210
microRNA, translational inhibition
699–706
NADPH oxidase, oxidative stress
173–182
- Cardiovascular risk
left ventricular hypertrophy, Type 2
diabetes 313–320
- Catecholamine
birthweight, renin–angiotensin
system 375–380

- Cell proliferation
energy metabolism, magnesium
27–35
- Chemosensitivity
heart failure, neurohormone
489–497
- Chemotaxis
atherosclerosis, ephrin-B
643–650
- Chlamydia pneumoniae*
atherosclerosis, cardiovascular
disease 509–531
- Cholestasis
bile, hepatocellular transport
567–588
- Chronic fatigue syndrome
arterial stiffness, inflammation
561–566
- Chronic obstructive pulmonary
disease
killer cell, T-lymphocyte
533–541
- Congestive heart failure
fluid balance, sodium 221–230
- Continuous positive airway pressure
heart rate variability, obstructive
sleep apnoea 243–249
- Coronary artery bypass grafting
angioplasty, pathology 211–220
cardiac magnetic resonance, risk
stratification 423–430
muscle, protein metabolism
339–346
- D**Developmental programming
blood pressure, cardiovascular
disease 1–17
- Diabetes
angiopoietin, wound healing
707–718
- Diabetic nephropathy
glomerular filtration pressure,
hyperfiltration 109–118
- Disease susceptibility
innate immune system, Toll-like
receptor 347–360
- Distensibility coefficient
arterial function, tissue Doppler
imaging 441–447
- Drug-eluting stent
antioxidant, oxidative stress
265–273
- Dyslipidaemia
apolipoprotein B, high-density
lipoprotein 149–155
- E**Endothelial function
fish oil fatty acid, postprandial
vascular reactivity 679–686
- Endothelin
hypertension, sex 85–97
- Endothelium-dependent relaxation
grape seed extract, polyphenol
331–337
- Energy expenditure
exercise, insulin sensitivity 59–64
- Energy metabolism
cell proliferation, magnesium 27–35
- Ephrin-B
atherosclerosis, chemotaxis
643–650
- Erythropoietin
ischaemia/reperfusion, myocardium
289–291, 293–304
- Essential hypertension
oxidative stress, vitamin 625–634
- Eukaryotic initiation factor
protein synthesis, total parenteral
nutrition 603–610
- Exercise
energy expenditure, insulin
sensitivity 59–64
pulmonary hypertension,
respiratory muscle strength
165–171
- F**Familial combined hyperlipidaemia
low-density lipoprotein,
triacylglycerol 393–401
- Fasting
intrahepatic lipid, non-alcoholic
fatty liver disease 543–545,
547–552
- Fish oil fatty acid
endothelial function, postprandial
vascular reactivity 679–686
- Fluid balance
congestive heart failure, sodium
221–230
- Fluorophore
microvascular permeability, sepsis
123–130
- G**Gender
albuminuria, quantitative trait locus
305–311
- Gene polymorphism
atrial natriuretic peptide, left
ventricular hypertrophy 131–137
- Glaucoma
adrenomedullin, calcitonin
receptor-like protein 49–58
- Glomerular filtration pressure
diabetic nephropathy,
hyperfiltration 109–118
- Glucagon
insulin resistance, Type 2 diabetes
589–590, 591–601
- Glucose disposal
imatinib mesylate, insulin sensitivity
65–71
- Glucose metabolism
protein restriction,
transgenerational programming
381–392
- Grape seed extract
endothelium-dependent relaxation,
polyphenol 331–337
- H**Heart failure
angiotensin-converting enzyme,
urocortin 2 635–642
chemosensitivity, neurohormone
489–497
- Heart rate variability
continuous positive airway
pressure, obstructive sleep
apnoea 243–249
- Hepatocellular carcinoma
angiogenesis, inflammation 467–477
- Hepatocellular transport
bile, cholestasis 567–588
- Hepatocyte
arginase-I, liver resection 231–241
innate immune system, natural killer
T-cell 457–466
proliferation, Ras 73–83
- High-density lipoprotein
apolipoprotein B, dyslipidaemia
149–155
- Homocysteine
microangiopathy, retina 479–487
- Hyperfiltration
diabetic nephropathy, glomerular
filtration pressure 109–118
- Hypertension
endothelin, sex 85–97
low-grade inflammation, soluble
CD40 ligand 449–455
middle cerebral artery, superoxide
anion 651–659
- I**Imatinib mesylate
glucose disposal, insulin sensitivity
65–71
- Inflammation
abdominal aortic aneurysm,
transcription factor 687–697

- angiogenesis, hepatocellular carcinoma 467–477
- arterial stiffness, chronic fatigue syndrome 561–566
- Innate immune system
- disease susceptibility, Toll-like receptor 347–360
 - hepatocyte, natural killer cell 457–466
- Ins(1,4,5) P_3
- adrenergic receptor, ischaemia/reperfusion 157–164
- Insulin resistance
- angiotensin II type 1 receptor, arterial stiffness 119–121, 139–147
 - glucagon, Type 2 diabetes 589–590, 591–601
- Insulin response
- proteomics, Type 2 diabetes 499–507
- Insulin sensitivity
- energy expenditure, exercise 59–64
 - glucose disposal, imatinib mesylate 65–71
- Interleukin-8
- acute lung injury, autoantibody 403–412
- Intrahepatic lipid
- fasting, non-alcoholic fatty liver disease 543–545, 547–552
- Ischaemia/reperfusion
- adrenergic receptor, Ins(1,4,5) P_3 157–164
 - antioxidant, liver 553–560
 - erythropoietin, myocardium 289–291, 293–304
- K**iller cell
- chronic obstructive pulmonary disease, T-lymphocyte 533–541
- L**eft ventricular hypertrophy
- atrial natriuretic peptide, gene polymorphism 131–137
 - cardiomyopathy, myosin heavy chain 431–440
 - cardiovascular risk, Type 2 diabetes 313–320
- Lipid
- metabolic syndrome, obesity 183–193
- Liver
- antioxidant, ischaemia/reperfusion 553–560
- Liver resection
- arginase-1, hepatocyte 231–241
- Low-density lipoprotein
- familial combined hyperlipidaemia, triacylglycerol 393–401
- Low-grade inflammation
- hypertension, soluble CD40 ligand 449–455
- Lung disease
- airway, stem cell 99–108
- Lymphocytic hypophysitis
- autoimmune disease, pituitary gland 413–421
- M**agnesium
- cell proliferation, energy metabolism 27–35
- Metabolic syndrome
- apolipoprotein C-III, cardiovascular disease 611–624
 - cardiovascular disease, mitochondrion 195–210
 - lipid, obesity 183–193
- Microangiopathy
- homocysteine, retina 479–487
- MicroRNA
- cardiovascular disease, translational inhibition 699–706
- Middle cerebral artery
- hypertension, superoxide anion 651–659
- Mineralocorticoid receptor
- aldosterone, stroke 37–47
- Microvascular permeability
- fluorophore, sepsis 123–130
- Mitochondrion
- cardiovascular disease, metabolic syndrome 195–210
- Muscle
- coronary artery bypass grafting, protein metabolism 339–346
- Muscle strength
- age, balance 719–727
- Myocardium
- erythropoietin, ischaemia/reperfusion 289–291, 293–304
- Myosin heavy chain
- cardiomyopathy, left ventricular hypertrophy 431–440
- N**ADPH oxidase
- cardiovascular disease, oxidative stress 173–182
- Natural killer cell
- hepatocyte, innate immune system 457–466
- Neurohormone
- chemosensitivity, heart failure 489–497
- Non-alcoholic fatty liver disease
- fasting, intrahepatic lipid 543–545, 547–552
- O**besity
- adiponectin, visfatin, 275–288
 - adiponectin, cardiovascular disease 361–374
 - lipid, metabolic syndrome 183–193
- Obstructive sleep apnoea
- continuous positive airway pressure, heart rate variability 243–249
- Oxidative stress
- antioxidant, drug-eluting stent 265–273
 - cardiovascular disease, NADPH oxidase 173–182
 - essential hypertension, vitamin 625–634
- P**athology
- angioplasty, coronary artery bypass grafting 211–220
- Percutaneous coronary intervention
- atherosclerosis, vitamin A 19–25
- Pituitary gland
- autoimmune disease, lymphocytic hypophysitis 413–421
- Polyphenol
- endothelium-dependent relaxation, grape seed extract 331–337
- Postprandial vascular reactivity
- endothelial function, fish oil fatty acid 679–686
- Proliferation
- hepatocyte, Ras 73–83
- Protein metabolism
- coronary artery bypass grafting, muscle 339–346
- Protein restriction
- glucose metabolism, transgenerational programming 381–392
- Protein synthesis
- eukaryotic initiation factor, total parenteral nutrition 603–610
- Proteomics
- insulin response, Type 2 diabetes 499–507

- Pulmonary hypertension
exercise, respiratory muscle
strength 165–171
- Quantitative trait locus**
albuminuria, gender 305–311
- Ras**
hepatocyte, proliferation 73–83
- Remodelling
angioplasty, restenosis 257–264
- Renin–angiotensin system
birthweight, catecholamine
375–380
- Respiratory muscle strength
exercise, pulmonary hypertension
165–171
- Restenosis
angioplasty, remodelling 257–264
- Retina
homocysteine, microangiopathy
479–487
- Risk stratification
cardiac magnetic resonance,
coronary artery bypass grafting
423–430
- Sepsis**
fluorophore, microvascular
permeability 123–130
- Sex
endothelin, hypertension 85–97
- Sodium
congestive heart failure, fluid
balance 221–230
- Soluble CD40 ligand
hypertension, low-grade
inflammation 449–455
- Stem cell
airway, lung disease 99–108
- Stroke
aldosterone, mineralocorticoid
receptor 37–47
- Superoxide anion
hypertension, middle cerebral
artery 651–659
- Tissue Doppler imaging**
arterial function, distensibility
coefficient 441–447
- T-lymphocyte
chronic obstructive pulmonary
disease, killer cell 533–541
- Toll-like receptor
disease susceptibility, innate
immune system 347–360
- Total parenteral nutrition
eukaryotic initiation factor, protein
synthesis 603–610
- Transcription factor
abdominal aortic aneurysm,
inflammation 687–697
- Transgenerational programming
glucose metabolism, protein
restriction 381–392
- Translational inhibition
cardiovascular disease, microRNA
699–706
- Triacylglycerol
familial combined hyperlipidaemia,
low-density lipoprotein 393–401
- Type 2 diabetes
albumin, antioxidant 251–256
cardiovascular risk, left ventricular
hypertrophy 313–320
glucagon, insulin resistance
589–590, 591–601
insulin response, proteomics
499–507
- Urocortin 2**
angiotensin-converting enzyme,
heart failure 635–642
- Visfatin**
adiponectin, obesity 275–288
- Vitamin
essential hypertension, oxidative
stress 625–634
- Vitamin A
atherosclerosis, percutaneous
coronary intervention 19–25
- Wound healing**
angiopoietin, wound healing
707–718